MTOR and cancer: Because mTOR inhibitors and drugs targeting molecules upstream of mTOR, such as PI3K inhibitors, are approved for treatment of cancer (35–37), it is essential to elucidate the role of mTOR in T cell exhaustion to further improve immunotherapy for patients with cancer.